GILD
Gilead Sciences, Inc.
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14.5B | 10.0B | 10.8B | 8.0B | 9.1B | 11.4B | 8.2B | 9.1B | 8.4B | 11.9B | 17.0B | 21.3B | 12.8B | 3.1B | 3.2B | 3.6B | 2.8B | 3.1B | 2.1B | 1.7B |
| 699M | 563M | 523M | 585M | 728M | 579M | 650M | 825M | 924M | — | — | — | — | 134M | — | — | — | — | — | — | |
| Free cash flow | 13.8B | 9.5B | 10.3B | 7.4B | 8.3B | 10.8B | 7.5B | 8.3B | 7.5B | — | — | — | — | 3.0B | — | — | — | — | — | — |
| Depreciation and amortization | 2.81B | 2.76B | 2.77B | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B | 1.10B | 1.05B | 0.35B | 0.28B | 0.30B | 0.27B | 0.21B | 0.16B | 0.10B |
| Stock-based compensation | 913M | 894M | 835M | 766M | 637M | 635M | 643M | 636M | 845M | 638M | 380M | 382M | 360M | 252M | 209M | 192M | 200M | 181M | 153M | 185M |
| Buybacks | 1.4B | 1.9B | 1.2B | 1.0B | 1.4B | 546M | 1.6B | 1.7B | 2.9B | 954M | 11.0B | 10.0B | 5.3B | 582M | 667M | 2.4B | 4.0B | 998M | 2.0B | 488M |
| Dividends paid | 4.10B | 4.00B | 3.92B | 3.81B | 3.71B | 3.61B | 3.45B | 3.22B | 2.97B | 2.73B | 2.46B | 1.87B | 0 | 0 | — | — | — | — | — | — |
| Dividends per share | 3.25 | 3.16 | 3.08 | 3.00 | 2.92 | 2.84 | 2.72 | 2.52 | 2.28 | 2.08 | 1.84 | 1.29 | 0.00 | 0.00 | — | — | — | — | — | — |
| Free cash flow margin | 44.5% | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% | 30.5% | 37.1% | 33.8% | — | — | — | — | 26.5% | — | — | — | — | — | — |